Veracyte Balance Sheet Health
Financial Health criteria checks 6/6
Veracyte has a total shareholder equity of $1.0B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.1B and $70.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$216.45m |
| Equity | US$1.04b |
| Total liabilities | US$70.80m |
| Total assets | US$1.11b |
Recent financial health updates
No updates
Recent updates
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Valuing Veracyte Stock
Oct 03Financial Position Analysis
Short Term Liabilities: VCYT's short term assets ($285.6M) exceed its short term liabilities ($61.2M).
Long Term Liabilities: VCYT's short term assets ($285.6M) exceed its long term liabilities ($9.6M).
Debt to Equity History and Analysis
Debt Level: VCYT is debt free.
Reducing Debt: VCYT has no debt compared to 5 years ago when its debt to equity ratio was 31.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable VCYT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: VCYT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.7% per year.